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Abstract
The Cancer and Leukemia Group B has performed central review of karyotypes submitted by
institutional cytogenetics laboratories from patients with acute myeloid (AML) and acute
lymphoblastic (ALL) leukemia since 1986. We assessed the role of central karyotype review in
maintaining accurate, high quality cytogenetic data for clinical and translational studies using two
criteria: the proportion of karyotypes rejected (i.e. inadequate), and, among accepted (i.e.
adequate) cases, the proportion of karyotypes whose interpretation was changed on central
karyotype review. We compared the first four years during which central karyotype review was
performed with a recent four-year period and found that the proportion of rejected samples
decreased significantly for both AML and ALL. However, during the latter period, central
karyotype reviews still found 8% of AML and 16% of ALL karyotypes inadequate. Among
adequate cases, the karyotype was revised in 26% of both AML and ALL samples. Some revisions
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resulted in changing the patients’ assignment to particular World Health Organization diagnostic
categories and/or moving patients from one prognostic group to another. Overall, when both data
on rejection rates and data on karyotype revisions made in accepted cases were considered
together, 32% of AML and 38% of ALL samples submitted were either rejected or revised on
central karyotype review during the recent 4-year period. These data underscore the necessity of
continued central karyotype review in multi-institutional cooperative group studies.
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Introduction
Cytogenetic findings have become an integral part of diagnosis, prognostication and
therapeutic stratification of acute myeloid leukemia (AML) and acute lymphoblastic
leukemia (ALL). Such recurrent chromosome abnormalities and their molecular equivalents
as t(8;21)(q22;q22)/RUNX1-RUNX1T1, inv(16)(p13q22)/t(16;16)(p13;q22)/CBFB-
MYH11, t(15;17)(q22;q12–21)/PML-RARA, and balanced abnormalities involving band
11q23 and the MLL gene are now included in the World Health Organization (WHO)
classification of AML, and together with morphology, immunophenotype and clinical
features are being used to define distinct disease entities (1). Notably, the role of
cytogenetics will be substantially increased in the 2008 revision of the WHO classification
(2).
Moreover, pretreatment cytogenetic findings constitute one of the most important prognostic
factors in both AML (3–10) and ALL (7,11–13), are used to determine postremission
therapy (14–17), and are important for molecular genetic studies investigating mutations
(18–29) and changes in expression of specific genes (30–32), as well as gene- (33–37) and
microRNA-expression (38,39) profiles in patients with acute leukemias. Importantly, the
National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology
specify that cytogenetic analysis is an obligatory part of the diagnostic workup in AML (40).
Likewise, cytogenetic analysis is one of the minimum laboratory requirements for the
diagnosis of AML according to the “Guidelines on the Management of Acute Myeloid
Leukaemia in Adults” issued by the British Committee for Standards in Haematology (41).
Consequently, the Cancer and Leukemia Group B (CALGB) now mandates cytogenetic
analyses for adult AML and ALL front-line treatment trials and many correlative studies. It
is therefore imperative that cytogenetic data are accurate.
Despite continuous improvements in cytogenetic methodology, not all cytogenetic studies of
bone marrow (BM) or blood from patients with acute leukemia are successful. In addition to
a fraction of cases in which BM or blood cultures yield no mitotic cells, some cytogenetic
preparations from leukemic samples are of suboptimal quality. This can make correct
interpretation of karyotypes difficult. It has long been recognized that metaphase
chromosomes of leukemic cells (especially, but not exclusively, from ALL patients) often
have poor morphology with indistinct banding (42). Furthermore, a remarkable
heterogeneity of chromosome findings in acute leukemias, with over two hundred
recognized recurrent aberrations, many of which are relatively rare having been reported in
less than 10 cases worldwide (43–45), underscores the necessity for cytogeneticists
analyzing patients with AML and ALL to have vast experience in leukemia cytogenetics.
Therefore, CALGB pioneered the central review of karyotypes, which has been performed
biannually since 1986 (46). In the current study, we evaluated the role of central karyotype
Mrózek et al. Page 2













review in providing accurate cytogenetic data. Our analysis shows an improvement in the
quality of submitted karyotypes over time but also confirms the continued need for
performing central karyotype review in the multi-institutional cooperative group setting to
obtain the best possible data for clinical and translational studies.
Patients and Methods
Cytogenetic analyses of diagnostic (n=5259) and relapse (n=909) samples from patients
with AML and ALL enrolled onto a prospective cytogenetic companion study, CALGB
8461 (5), were performed in multiple, currently 33, CALGB-approved institutional
cytogenetic laboratories. Written IRB-approved informed consent was obtained from all
patients. For each specimen, two karyotypes and metaphase spreads from each clone were
submitted with the data on processing methods to the CALGB Cytogenetic Data
Management Center. If applicable, images of interphase and/or metaphase cells subjected to
fluorescence in situ hybridization (FISH) were also submitted. All cases underwent biannual
central karyotype review performed by the CALGB Karyotype Review Committee
consisting often expert cancer cytogeneticists. At central karyotype review sessions, every
karyotype, metaphase spread, FISH image, and processing and interpretive data were
reviewed by two cytogeneticists. In some cases, usually those with more complex
chromosome abnormalities and/or with suboptimal banding quality, other reviewers also
rendered their opinion. Once consensus was reached, each submission was judged as either
acceptable with adequate banding quality, acceptable with borderline banding quality, or
inadequate and consequently rejected. Reasons for rejection included poor banding quality
that makes unequivocal karyotype interpretation impossible, and, only in cases with a
normal karyotype, analysis of <20 metaphase cells from a marrow sample cultured for 24–
48 hours or analysis of blood only (5). Since the aim of this study was to assess the role of
central karyotype review, our analyses did not include 202 AML and 125 ALL cases for
whom cytogenetic analysis yielded no metaphase cells.
In addition to data on rejection rates collected routinely at each central karyotype review, for
the purpose of this study, we prospectively collected detailed information on the reasons for
revisions made by central karyotype review in the submitted karyotypes that were accepted
or borderline accepted during eight recent central karyotype review sessions. The reasons for
revision were divided into the following categories: 1) major errors in karyotype
interpretation, such as failure of the submitting laboratory to recognize a clonal abnormality,
identification of an abnormality found on central karyotype review not to be present, and
incorrect interpretation of an abnormality; 2) the need for refinement of breakpoint
assignment in structural abnormalities properly recognized by the submitting laboratory, 3)
misidentified or upside-down chromosomes, and 4) incorrect use of the ISCN (1995)
nomenclature (47). In this study, we excluded samples analyzed cytogenetically during
complete remission, because these samples differ from pretreatment and relapse samples in
that they rarely contain leukemic cells and are usually karyotypically normal (48). The
rejection rates between the first and the recent four-year periods (Table I) have been
compared using the Fisher’s Exact test. All analyses were performed by the CALGB
Statistical Center.
Results and Discussion
Table I shows rejection rates and reasons for rejection for AML and ALL specimens that
underwent central karyotype review during the entire period between 1986 and 2006.
Overall, 12% of 4991 AML and 23% of 1177 ALL karyotypes submitted were rejected. The
most common reason for rejection was inadequate banding quality, which accounted for
rejection of 53% (325 of 612) of AML and 46% (123 of 270) of ALL inadequate cases.
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When we compared rejection rates between the first four years during which central
karyotype review was performed and the recent four-year period, we found a significant
improvement in the quality of submitted specimens in both AML (P<0.0001) and ALL
(P<0.001). This was mainly due to the significant decrease in the numbers of karyotypes
with inadequate banding quality (AML, P<0.0001 and ALL, P=0.02). Nevertheless, the
recent central karyotype reviews still found 8% of AML and 16% of ALL samples
inadequate.
Another indication of the quality improvement over time was an increase in the proportion
of abnormal karyotypes pretreatment, from 52% in the first 4 years to 57% in the recent 4
years (P=0.05) in AML and from 59% to 75% in ALL (P=0.007). These improvements in
quality can be attributed to many factors, including progress in cell culturing, harvesting and
banding techniques, as well as increase in proficiency in analyzing specimens from patients
with acute leukemias. The latter has been achieved in part through feedback provided to
cytogeneticists from the submitting laboratories after central karyotype review sessions and
through educational workshops organized and conducted by the members of the Karyotype
Review Committee during CALGB Group Meetings.
Among karyotypes deemed to have adequate banding at 8 recent Central Karyotype Review
sessions, changes in karyotype interpretation were made in 26% of both AML and ALL
cases (Table II). The revisions included identification of an unrecognized chromosome
abnormality or reinterpretation of an abnormality incorrectly interpreted by the submitting
laboratory (44% of all revisions), reassignment of breakpoints in structural aberrations
(22%), correction of misidentified or upside-down chromosomes (22%), and correction of
errors in the ISCN (1995) nomenclature (12%).
In several instances, major changes in karyotype interpretation made on central karyotype
review resulted in moving patients from one diagnostic category in the current WHO
classification (1) to another. For example, AML patients whose karyotypes submitted as
normal were revised to abnormal ones that harbored t(9;11)(p22;q23),t(11;19)(q23;p13.1) or
inv(16)(p13q22), as well as patients whose submitted karyotype was changed from 46,X,−Y,
+8 to 46,X,−Y,+8,t(9;11)(p22;q23), from 46,XX,t(10;11)(p14;q13) to 46,XX,ins(10;11)
(p12;q23q13), from 46,XY,del(5)(q13q33),del(11)(q23) to 46,XY,del(5)(q13q33),t(6;11)
(q27;q23), and from 46,XY,del(3)(p13),add(11)(q23),−18, −21,+mar to 46,XY,t(3;11)
(p13;q23),add(18)(q21), −21 would be reclassified from having “AML not otherwise
categorized” to “AML with recurrent cytogenetic abnormalities”. Conversely, the patient
whose submitted complex karyotype included an inv(16)(p13q22) that was revised on
central karyotype review to der(16)add(16)(p13)del(16)(q22) would be reclassified from
having “AML with recurrent cytogenetic abnormalities” to “AML not otherwise
categorized“. There would be multiple additional changes in diagnostic categories once the
new 2008 edition of the WHO classification (2) is published, including, for example, a
reclassification from “AML with myelodysplasia related changes” to “AML with recurrent
genetic abnormalities” for the patient whose karyotype submitted as normal was found on
central karyotype review to contain an inv(3)(q21q26).
Many of both the aforementioned and other karyotype revisions made on central karyotype
review resulted in changes in prognostic group assignment of the patients. For instance,
revisions from a normal karyotype to a karyotype containing inv(3)(q21q26) or t(11;19)
(q23;p13.1), or from del(11)(q23) to t(6;11)(q27;q23) meant that these patients were no
longer classified as having an intermediate risk but were included in the adverse risk
category instead (5). Poor prognosis associated with an isolated trisomy of chromosome 13
(49) was no longer predicted in a patient whose karyotype was revised from 47,XY,+13 to
47,XY,+15 when the reviewers discovered that an extra chromosome submitted as
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chromosome 13 was in fact an extra chromosome 15 placed upside-down in the karyotype
of borderline quality. To date, prognostic significance of isolated trisomy 15 is unclear and it
has been suggested to represent a benign, age-related abnormality in older male patients
(50,51). Moreover, identification of an initially unrecognized inv(16) alters the patient’s risk
assignment from intermediate to favorable, whereas revision of the submitted inv(16) to
der(16)add(16)(p13)del(16)(q22) as part of a complex karyotype means that the patient’s
risk-group assignment is no longer favorable but becomes adverse. Importantly,
documentation of the presence or absence of inv(16) is of major clinical importance (52)
because the postremission therapy of AML patients with inv(16) on CALGB protocols is
administered in a risk-adapted fashion and includes three courses of high-dose cytarabine,
whereas patients without inv(16) [or t(8;21)] receive autologous peripheral stem-cell
transplantation (15).
Finally, we evaluated both the data on karyotype revisions made in the accepted cases and
data on rejection rates during the recent 4-year period. Overall, 32% of AML and 38% of
ALL samples submitted were either rejected or revised on central karyotype review.
While several studies have addressed the issue of proficiency testing and quality control in
clinical cytogenetics (53–55), to our knowledge only one other study (from the Children’s
Oncology Group), published in abstract form, has reported the cooperative group experience
concerning central review of karyotypes from acute leukemia patients (Heerema, et al,
Cytogenet Genome Res 106: 136, 2004). Results of this study are remarkably similar to
ours, showing that the karyotype was either changed or rejected in 31% of AML and 49% of
ALL pediatric cases submitted. Therefore, we conclude that central karyotype review plays
a vital role in ensuring the validity of the clinical trials and correlative studies conducted by
both adult and children’s cooperative groups.
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Wake Forest University School of Medicine, Winston-Salem, NC: David D. Hurd, Harold
O. Goodman, P. Nagesh Rao, Wendy L. Flejter and Mark J. Pettenati (grant no. CA03927);
North Shore University Hospital, Manhasset, NY: Daniel R. Budman, Natalie B. Kardon
and Prasad R. K. Koduru (grant no. CA35279); Roswell Park Cancer Institute, Buffalo, NY:
Ellis G. Levine, Avery A. Sandberg and AnneMarie W. Block (grant no. CA02599); The
Ohio State University Medical Center, Columbus, OH: Clara D. Bloomfield, Karl S. Theil,
Diane Minka and Nyla A. Heerema (grant no. CA77658); Dana-Farber Cancer Institute,
Boston, MA: Eric P. Winer, Ramana Tantravahi, Cynthia C. Morton, Leonard L. Atkins and
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Paola Dal Cin (grant no. CA32291); Duke University Medical Center, Durham, NC: Jeffrey
Crawford, Sandra H. Bigner, Mazin B. Qumsiyeh and Barbara K. Goodman (grant no.
CA47577); Weill Medical College of Cornell University, New York, NY: John Leonard,
Ram S. Verma,* Prasad R. K. Koduru, Andrew J. Carroll and Susan Mathew (grant no.
CA07968); University of Maryland Cancer Center, Baltimore, MD: Martin Edelman, Joseph
R. Testa, Deana Hallman, Stuart Schwartz, Maimon M. Cohen, Judith Stamberg and Yi
Ning (grant no. CA31983); University of Iowa Hospitals, Iowa City, IA: Gerald H. Clamon
and Shivanand R. Patil (grant no. CA47642); University of Chicago Medical Center,
Chicago, IL: Gini Fleming, Diane Roulston, Katrin M. Carlson, Yanming Zhang and
Michelle M. Le Beau (grant no. CA41287); University of North Carolina, Chapel Hill, NC:
Thomas Shea and Kathleen W. Rao (grant no. CA47559); Washington University School of
Medicine, St. Louis, MO: Nancy L. Bartlett, Christine G. Janney, Eric C. Crawford, Jaime
Garcia-Heras and Michael S. Watson (grant no. CA77440); Dartmouth Medical School,
Lebanon, NH: Marc S. Ernstoff, Doris H. Wurster-Hill* and Thuluvancheri K. Mohandas
(grant no. CA04326); Rhode Island Hospital, Providence, RI: William Sikov, Teresita
Padre-Mendoza, Jennifer A. Ahearn, Philip L. Townes, Hon Fong L. Mark, Shelly L.
Kerman and Aurelia Meloni-Ehrig (grant no. CA08025); University of Alabama at
Birmingham: Robert Diasio and Andrew J. Carroll (grant no. CA47545); SUNY Upstate
Medical University, Syracuse, NY: Stephen L. Graziano, Navnit S. Mitter, Edward J.
Hallinan, Lawrence P. Gordon and Constance K. Stein (grant no. CA21060); Christiana
Care Health Services, Inc., Newark, DE: Stephen S. Grubbs, Digamber S. Borgaonkar,
Jeanne M. Meck and Kathleen Richkind (grant no. CA45418); University of Missouri/Ellis
Fischel Cancer Center, Columbia, MO: Michael C. Perry, Judith H. Miles, Jeffrey R.
Sawyer, Tim H. Huang and Linda M. Pasztor (grant no. CA12046); Long Island Jewish
Medical Center CCOP, Lake Success, NY: Kanti R. Rai, Alan L. Shanske and Prasad R. K.
Koduru (grant no. CA11028); Minneapolis VA Medical Center, Minneapolis, MN: Vicki A.
Morrison and Sugandhi A. Tharapel (grant no. CA47555); University of California, San
Diego, CA: Barbara A. Parker, Oliver W. Jones, E. Robert Wassman, Renée Bernstein* and
Marie L. Dell'Aquila (grant no. CA11789); Walter Reed Army Medical Center, Washington,
DC: Thomas Reid, Rawatmal B. Surana, Syed K. Rafi, Doris H. Wurster-Hill,* Digamber S.
Borgaonkar, Karl S. Theil, Diane Minka, Nyla A. Heerema and Kathleen E. Richkind (grant
no. CA26806); Parkview Hospital, Ft. Wayne, IN: Sreenivasa Nattam and Patricia I. Bader;
University of Minnesota, Minneapolis, MN: Bruce A. Peterson, Betsy A. Hirsch and Diane
C. Arthur (grant no. CA16450); Mount Sinai School of Medicine, New York, NY: Lewis R.
Silverman and Vesna Najfeld (grant no. CA04457); University of Massachusetts Medical
School, Worcester, MA: William W. Walsh, Philip L. Townes, Vikram Jaswaney Kathleen
E. Richkind, Michael J. Mitchell and Patricia Miron (grant no. CA37135); Massachusetts
General Hospital, Boston, MA: Jeffrey W. Clark, Cynthia C. Morton, Paola Dal Cin and
Leonard L. Atkins (grant no. CA12449); Eastern Maine Medical Center, Bangor, ME:
Harvey M. Segal and Laurent J. Beauregard (grant no. CA35406); University of Vermont,
Burlington, VT: Hyman B. Muss, Elizabeth F. Allen and Mary Tang (grant no. CA77406);
Western Pennsylvania Hospital, Pittsburgh, PA: Richard K. Shadduck and Gerard R.
Diggans; University of Illinois, Chicago, IL: David J. Peace, Maureen M. McCorquodale,
Kathleen E. Richkind and Valerie Lindgren (grant CA74811); Medical College of Virginia/
Virginia Commonwealth University, Richmond, VA: John D. Roberts and Colleen Jackson-
Cook (grant no. CA52784); Columbia-Presbyterian Medical Center, New York, NY: Rose
R. Ellison and Dorothy Warburton (grant no. CA12011); Finsen Institute, Copenhagen,
Denmark: Nis I. Nissen and Preben Philip; McGill Department of Oncology, Montreal,
Quebec: J. L. Hutchison and Jacqueline Emond (grant no. CA31809); University of Puerto
Rico School of Medicine, San Juan, PR: Eileen I. Pacheco, Ramana Tantravahi, Cynthia C.
Morton, Paola Dal Cin and Leonard L. Atkins; Georgetown University Medical Center,
Washington, DC: Minnetta C. Liu and Jeanne M. Meck (grant no. CA77597); SUNY
Maimonides Medical Center, Brooklyn, NY: Sameer Rafla and Ram S. Verma* (grant no.
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CA25119); University of Nebraska Medical Center, Omaha, NE: Anne Kessinger and
Warren G. Sanger (grant no. CA77298); Medical University of South Carolina, Charleston,
SC: Mark R. Green, Eduardo S. Cantu, G. Shashidhar Pai and Daynna J. Wolff (grant no.
CA03927); University of California, San Francisco, CA: Charles J. Ryan, Athena M. Cherry
and Kathleen E. Richkind (grant no. CA60138); Southern Nevada Cancer Research
Foundation CCOP, Las Vegas, NV: John Ellerton, Oliver W. Jones, E. Robert Wassman,
Renée Bernstein* and Marie L. Dell'Aquila (grant no. CA35421); University of Cincinnati
Medical Center, Cincinnati, OH: Orlando J. Martelo and Ashok K. Srivastava (grant no.
CA47515); Kansas City CCOP, Kansas City, MO: Rakesh Gaur and Linda Cooley; South
East Cancer Control Consortium, Winston-Salem, NC: James N. Atkins and Mark J.
Pettenati (grant no. CA45808).
*Deceased.
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Table II
Changes in karyotype interpretation made in accepted AML and ALL cases during 8 recent central karyotype
review sessions
Changes in karyotype interpretation made by central karyotype review Total n=1138 AML n=1031 ALL n=107
No. (%) of samples reviseda 300 (26%) 272 (26%) 28 (26%)
Total no. of changes madea 446 404 42
Type of revision:
  Recognition of a missed abnormality or change in abnormality description (%) 195 (44%) 176 (43%) 19 (45%)
  Change in breakpoint(s) assignment (%) 100 (22%) 83 (21%) 17 (40%)
  Correction of misidentified or upside-down chromosome(s) (%) 98 (22%) 95 (24%) 3 (7%)
  Correction in ISCN (1995) nomenclature (%) 53 (12%) 50 (12%) 3 (7%)
a
Some karyotypes required two or more corrections.
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